PB0726 - (Factor VIII / Factor V) Ratio as a New Prognostic Marker for Decompensated Liver Cirrhosis

Monday, July 11, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: Virtual

Presenting Author(s)

Mohamed El Horri, Sr., PharmD , AssProf LabHaem

Head of Laboratory Haematology Unit
Regional Military University Hospital of Oran
Oran, Oran, Algeria

Co-Author(s)

NF

Narimene Feghoul

Laboratory Haematology Unit
Regional Military University Hospital of Oran
Oran, Oran, Algeria
FE

Fatima El Horri

Department of Pediatrics
Mixed Hospital of Ras elma
Sidi Bel Abbes, Sidi Bel Abbes, Algeria
IK

Ibrahim Khachaa

Head od Blood Bank Unit
Regional Military University Hospital of Oran
Oran, Oran, Algeria
AC

Abdelkrim Chikh Khelifa

Laboratory Haematology Unit
Regional Military University Hospital of Oran
Saida, Saida, Algeria
MB

Malika Baghdadi

Chief of Department of Hepatology Gastro-Enterology
Regional Military University Hospital of Oran
Oran, Oran, Algeria
AB

Abderrezak Benglia

Head of Biochemistry Unit
Regional Military University Hospital of Oran
Oran, Oran, Algeria
KB

Khadidja Benbouhadi

Laboratory Haematology Unit
Regional Military University Hospital of Oran
Oran, Oran, Algeria
HM

Hanaa Mimene

Blood Bank Unit
Regional Military University Hospital of Oran
Oran, Oran, Algeria
KK

Khalil Kebir

Laboratory Haematology Unit
Regional Military University Hospital of Oran
Oran, Oran, Algeria
KB

Khadidja Benhalima

Blood Bank Unit
Regional Military University Hospital of Oran
Oran, Oran, Algeria
LB

Lahcene Benmahdi

Chief of Department of Laboratory Medicine
Regional Military University Hospital of Oran
Oran, Oran, Algeria
BH

Brouk Hacene

Professor
Hemobiology and blood transfusion
Annaba, Annaba, Algeria

Background: Factor VIII is synthesized by the liver but also by endothelial cells. Thus, its concentration does not decrease with liver cirrhosis and may even be increased due to endothelial dysfunction. But this increase does not correlate with the worsening of the disease due to the deterioration of liver function. Therefore we hypothetically assumed that the expression of factor VIII according to factor V could fill this gap.

Aims: To assess the prognosis value of the RATIO (Factor VIII / Factor V) in predicting mortality in decompensated hepatic cirrhosis.

Methods: A prospective cohort was conducted on 60 decompensated cirrhotic patients. All these patients got a measurement of factor VIII and factor V and the ratio was calculated. The endpoint was the occurrence of death.

Results: Patients were followed for a median of 15 months, after which 38% of death cases were noticed and we recorded one tracking lost.
The ratio (FVIII/FV) was significantly higher in deceased patients compared to survivors: 5.79 [CI: 4.36–7.21] versus 3.49 [CI: 2.91–3.98]; p=0.001.
The threshold value of 4.76 for our ratio which made it possible to predict death with a sensitivity of 56.52% and a specificity of 89%. Patients with a ratio < 4.76 (group I): had a mean survival of 17.3 months and a survival probability of 75.5% at 12 months. Those whose ratio exceeded 4.76 (group II): had a mean survival of 4.6 months with a survival probability of 60.8% at 12 months. Patients in group II had higher risk of mortality than those in group I , with a HR = 4.5 [IC: 1,95 – 10,35].

Conclusion(s): The ratio (FVIII/FV) is a good prognosis marker allowing the prediction of mortality in decompensated cirrhotic patients, independently of the Child Pugh and MELD score.The results found are promising and should arouse the interest of researchers in this field.